Finance Watch: Recent M&A Uptick Gives Biopharma A Needed Boost
Restructuring Continues, However, As Firms Conserve Cash
Public Company Edition: William Blair analysts note that stock prices are rising due to a Q2 boost in dealmaking after a lull in Q1. Nevertheless, layoffs and portfolio prioritizations are ongoing, including at X4 Pharmaceuticals, but others have raised cash following good news, like Revolution Medicines.
